{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:55:54Z","timestamp":1781650554479,"version":"3.54.5"},"reference-count":19,"publisher":"Norwegian Medical Association","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tidsskr Nor Legeforen","Tidsskriftet"],"published-print":{"date-parts":[[2014,3,25]]},"DOI":"10.4045\/tidsskr.13.0925","type":"journal-article","created":{"date-parts":[[2014,3,26]],"date-time":"2014-03-26T10:31:50Z","timestamp":1395829910000},"page":"620-3","source":"Crossref","is-referenced-by-count":1,"title":["Polypillen som kardiovaskul\u00e6r profylakse \u2013 kliniske studier"],"prefix":"10.4045","volume":"134","author":[{"given":"Oda Kristine","family":"Sandli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7902-9014","authenticated-orcid":false,"given":"Olav","family":"Spigset","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Sl\u00f8rdal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2479","reference":[{"key":"ref=1","unstructured":"World Health Organization. Cardiovascular diseases \u2013 World Heart Day 2013. www.who.int\/cardiovascular_diseases\/en\/index.html (5.1.2014)."},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"Sandli O, Spigset O, Sl\u00f8rdal L. Polypillen \u2013 et alternativt konsept i kardiovaskul\u00e6r profylakse. Tidsskr Nor Legeforen 2014; 134: 632\u2009\u2013\u20094.","DOI":"10.4045\/tidsskr.13.0924"},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80\u00a0%. BMJ 2003; 326: 1419. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12829553&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1136\/bmj.326.7404.1419","DOI":"10.1136\/bmj.326.7404.1419"},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"Yusuf S, Pais P, Afzal R et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 2009; 373: 1341\u2009\u2013\u200951. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19339045&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/S0140-6736(09)60611-5","DOI":"10.1016\/S0140-6736(09)60611-5"},{"key":"ref=5","doi-asserted-by":"crossref","unstructured":"Malekzadeh F, Marshall T, Pourshams A et al. A\u00a0pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy (\u00abpolypill\u00bb) on cardiovascular risk factors. Int J Clin Pract 2010; 64: 1220\u2009\u2013\u20097. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20653798&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111\/j.1742-1241.2010.02412.x","DOI":"10.1111\/j.1742-1241.2010.02412.x"},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"Soliman EZ, Mendis S, Dissanayake WP et al. A\u00a0Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization. Trials 2011; 12: 3. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21205325&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1186\/1745-6215-12-3","DOI":"10.1186\/1745-6215-12-3"},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"Rodgers A, Patel A, Berwanger O et al. An international randomised placebo-controlled trial of a\u00a0four-component combination pill (\u00abpolypill\u00bb) in people with raised cardiovascular risk. PLoS ONE 2011; 6: e19857. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21647425&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1371\/journal.pone.0019857","DOI":"10.1371\/journal.pone.0019857"},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"Yusuf S, Pais P, Sigamani A et al. Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators. Circ Cardiovasc Qual Outcomes 2012; 5: 463\u2009\u2013\u200971. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22787067&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1161\/CIRCOUTCOMES.111.963637","DOI":"10.1161\/CIRCOUTCOMES.111.963637"},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"Wald N, Law M. The Indian Polycap Study (TIPS). Lancet 2009; 374: 781, author reply 782. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19733775&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/S0140-6736(09)61584-1","DOI":"10.1016\/S0140-6736(09)61584-1"},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"O\u2019Donnell MJ, Yusuf S, Mente A et al. Urinary sodium and potassium excretion and risk of cardiovascular events. JAMA 2011; 306: 2229\u2009\u2013\u200938. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22110105&dopt=Abstract","DOI":"10.1001\/jama.2011.1729"},{"key":"ref=11","doi-asserted-by":"crossref","unstructured":"Wald DS, Morris JK, Wald NJ. Randomized Polypill crossover trial in people aged 50 and over. PLoS ONE 2012; 7: e41297. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22815989&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1371\/journal.pone.0041297","DOI":"10.1371\/journal.pone.0041297"},{"key":"ref=12","unstructured":"Clinicaltrials.gov. The International Polycap Study 3 (TIPS-3). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01646437?term=TIPS-3&rank=1 (5.1.2014)."},{"key":"ref=13","unstructured":"Clinicaltrials.gov. Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians Using a Single PolyPill (PolyIran). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01271985?term=polypill+malekzadeh&rank=3 (5.1.2014)."},{"key":"ref=14","unstructured":"Clinicaltrials.gov. UMPIRE \u2013 Use of a Multidrug Pill In Reducing Cardiovascular Events NCT01057537. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01057537 (5.1.2014)."},{"key":"ref=15","doi-asserted-by":"crossref","unstructured":"Liu H, Patel A, Brown A et al. Rationale and design of the Kanyini guidelines adherence with the polypill (Kanyini-GAP) study: a randomised controlled trial of a polypill-based strategy amongst indigenous and non indigenous people at high cardiovascular risk. BMC Public Health 2010; 10: 458. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20687931&dopt=Abstract","DOI":"10.1186\/1471-2458-10-458"},{"key":"ref=16","unstructured":"Platform ICTR. Improving Adherence using Combination Therapy IMPACT ACTRN12606000067572. http:\/\/apps.who.int\/trialsearch\/Trial.aspx?TrialID=ACTRN12606000067572 (5.1.2014.)"},{"key":"ref=17","unstructured":"Clinicaltrials.gov. Fixed Dose Combination Drug (Polypill) for Secondary Cardiovascular Prevention. (FOCUS) NCT01321255. http:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01321255 (5.1.2014)."},{"key":"ref=18","doi-asserted-by":"crossref","unstructured":"Rodgers A. A cure for cardiovascular disease? Combination treatment has enormous potential, especially in developing countries. BMJ 2003; 326: 1407\u2009\u2013\u20098. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12829526&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1136\/bmj.326.7404.1407","DOI":"10.1136\/bmj.326.7404.1407"},{"key":"ref=19","unstructured":"Wald N, Law MR. Inventor Formulation For The Prevention Of Cardiovascular Disease. Great Britain patent PT1272220. 2006. www.google.com\/patents\/US20030175344 (23.1.2014)."}],"container-title":["Tidsskrift for Den norske legeforening"],"original-title":[],"language":"no","deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:19:43Z","timestamp":1781648383000},"score":1,"resource":{"primary":{"URL":"https:\/\/tidsskriftet.no\/2014\/03\/oversiktsartikkel\/polypillen-som-kardiovaskulaer-profylakse-kliniske-studier"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,25]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,3,25]]}},"URL":"https:\/\/doi.org\/10.4045\/tidsskr.13.0925","relation":{},"ISSN":["0029-2001","0807-7096"],"issn-type":[{"value":"0029-2001","type":"print"},{"value":"0807-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,25]]}}}